Table 4.
Lenalidomide in clinical trials
| Study agents | Other agents | Disease | Dosage | Clinical trials | No.of Pts | Response | Reference |
|---|---|---|---|---|---|---|---|
| Lenalidomide |
|
Relapsed |
5/10/15 mg |
Phase II |
95 |
CR:2% |
[34] |
| Refractory |
ORR:79% |
||||||
| Lenalidomide |
Dexamethasone |
Untreated |
5 mg |
Phase II |
18 |
CR:6% |
[35] |
| ORR:59% | |||||||
| Lenalidomide |
Fludarabine |
Untreated |
2.5 mg |
Phase I/II |
64 |
CR:11% |
[36] |
| Rituximab |
Minimally |
|
|
|
ORR:63% |
|
|
| treated |
Abbreviations: ORR overall response rate, CR complete remission.